204 related articles for article (PubMed ID: 24217308)
1. Saxagliptin demonstrates no increased risk for cardiovascular death, heart attack or stroke in the SAVOR cardiovascular outcomes trial.
Hardy G
Cardiovasc J Afr; 2013 Aug; 24(7):290. PubMed ID: 24217308
[No Abstract] [Full Text] [Related]
2. Baseline differences in the SAVOR trial.
Luijendijk HJ; Hulshof TA
Diabetes Obes Metab; 2015 Dec; 17(12):1202. PubMed ID: 26094750
[No Abstract] [Full Text] [Related]
3. Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes.
Borja-Hart NL; Whalen KL
Ann Pharmacother; 2010 Jun; 44(6):1046-53. PubMed ID: 20460554
[TBL] [Abstract][Full Text] [Related]
4. No benefit of saxagliptin on cardiovascular outcomes in type 2 diabetes mellitus: potential explanations.
Jialal I; Dhindsa S
Metab Syndr Relat Disord; 2014 Apr; 12(3):157-8. PubMed ID: 24520851
[No Abstract] [Full Text] [Related]
5. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.
Mosenzon O; Raz I; Scirica BM; Hirshberg B; Stahre CI; Steg PG; Davidson J; Ohman P; Price DL; Frederich B; Udell JA; Braunwald E; Bhatt DL
Diabetes Metab Res Rev; 2013 Jul; 29(5):417-26. PubMed ID: 23564755
[TBL] [Abstract][Full Text] [Related]
6. Saxagliptin and tuberculosis.
Prescrire Int; 2013 Jan; 22(134):17. PubMed ID: 23383408
[No Abstract] [Full Text] [Related]
7. Lessons from SAVOR and EXAMINE: some important answers, but many open questions.
Schernthaner G; Sattar N
J Diabetes Complications; 2014; 28(4):430-3. PubMed ID: 24713467
[No Abstract] [Full Text] [Related]
8. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes.
Frederich R; Alexander JH; Fiedorek FT; Donovan M; Berglind N; Harris S; Chen R; Wolf R; Mahaffey KW
Postgrad Med; 2010 May; 122(3):16-27. PubMed ID: 20463410
[TBL] [Abstract][Full Text] [Related]
9. [SAVOR TIMI 53 - Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus].
Spinar J; Smahelová A
Vnitr Lek; 2013 Nov; 59(11):1003-7. PubMed ID: 24279445
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Mannucci E
Nutr Metab Cardiovasc Dis; 2014 Jul; 24(7):689-97. PubMed ID: 24793580
[TBL] [Abstract][Full Text] [Related]
11. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.
Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Price DL; Chen R; Udell J; Raz I
Am Heart J; 2011 Nov; 162(5):818-825.e6. PubMed ID: 22093196
[TBL] [Abstract][Full Text] [Related]
12. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Clifton P
Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
[TBL] [Abstract][Full Text] [Related]
13. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Frederich R; Wiviott SD; Hoffman EB; Cavender MA; Udell JA; Desai NR; Mosenzon O; McGuire DK; Ray KK; Leiter LA; Raz I;
N Engl J Med; 2013 Oct; 369(14):1317-26. PubMed ID: 23992601
[TBL] [Abstract][Full Text] [Related]
14. Saxagliptin for the treatment of diabetes - a focus on safety.
Cernea S; Cahn A; Raz I
Expert Opin Drug Saf; 2016 May; 15(5):697-707. PubMed ID: 26923222
[TBL] [Abstract][Full Text] [Related]
15. Exploration of the DPP-4 inhibitors with a focus on saxagliptin.
Shubrook JH; Colucci RA; Schwartz FL
Expert Opin Pharmacother; 2009 Dec; 10(17):2927-34. PubMed ID: 19929711
[TBL] [Abstract][Full Text] [Related]
16. Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin.
Pollack PS; Chadwick KD; Smith DM; Billger M; Hirshberg B; Iqbal N; Boulton DW
Cardiovasc Diabetol; 2017 Sep; 16(1):113. PubMed ID: 28903775
[TBL] [Abstract][Full Text] [Related]
17. [Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Cardiovascular safety in type 2 diabetics].
MMW Fortschr Med; 2014 Jul; 156(13):74-5. PubMed ID: 25318234
[No Abstract] [Full Text] [Related]
18. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Gallwitz B
IDrugs; 2008 Dec; 11(12):906-17. PubMed ID: 19051153
[TBL] [Abstract][Full Text] [Related]
19. Saxagliptin, alone or in combination. No fewer complications; more cases of heart failure?
Prescrire Int; 2014 Sep; 23(152):207. PubMed ID: 25325118
[TBL] [Abstract][Full Text] [Related]
20. Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.
Jain R
Adv Ther; 2015 Nov; 32(11):1065-84. PubMed ID: 26578430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
